Science
Are T cell ‘engagers’ the next big thing in autoimmune disease treatment?
Publication: Latest News from Science Magazine
Author: Mitch Leslie
Source published: 18/11/2026, 20:42:24 UTC
Briefing created: 18/11/2026, 21:06:43 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 18/11/2026, 20:42:24 UTC.
Briefings
Recent evidence suggests engineered antibodies could provide remission and safety advantages over cell therapies in autoimmune disease, potentially offering a safer alternative to current treatments.
Key points
- Engineered antibodies may produce remissions and offer safety benefits over cell therapies that have killed patients.
Context
This finding addresses a critical gap in autoimmune disease management, where cell therapies have historically resulted in severe adverse events.
Limitations
Evidence is limited to a single study; specific patient outcomes, dosing protocols, and long-term safety data remain unreported.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 18/11/2026, 21:06:43 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiagwsgd52ftqvl4pf3axhlp2ebqcj2nes5vjvfi6kc6trx5xjmedm